Lunai Bioworks Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RENB research report →
Price Chart
About the company
Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions.
- CEO
- David H. Weinstein
- IPO
- 2018
- Employees
- 25
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on RENB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $32.92M
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 476.29
- P/B
- -0.72
- EV/EBITDA
- -0.06
- Div Yield
- 0.00%
- Gross Margin
- -360.71%
- Op Margin
- -46991.97%
- Net Margin
- -612568.11%
- ROE
- 892.52%
- ROIC
- 120.87%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-188,966,000
- Net Income
- $-178,007,489-120.7%
- EPS
- $-1.08+87.1%
- OCF Growth
- +28.2%
- FCF Growth
- +28.7%
- 52W High
- $21.00
- 52W Low
- $1.12
- 50D MA
- $1.96
- 200D MA
- $4.41
- Beta
- 0.53
- RSI (14)
- 33
- Avg Volume
- 218.51K
No earnings-call transcripts are available for RENB yet.
- Free Float
- 42.8%
- Shares Outstanding
- 23.18M
- Float Shares
- 9.93M
of shares held by institutions
21 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 497.01K | ▼ 20.61K |
Held by 1 ETFs
Biggest fund positions in RENB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 25 | William Anderson Wittekind | other | 350,000 |
| Jan 21, 25 | van Tilburg Maurice | other | 1,000,000 |
| Jan 21, 25 | van Tilburg Maurice | other | 250,000 |
| Jan 21, 25 | Fuentes Nathen | other | 250,000 |
| Jan 6, 25 | Fuentes Nathen | other | 0 |
| Nov 4, 24 | Collins Mark Anthony | other | 120,968 |
| Nov 4, 24 | Calder Douglas W | other | 120,968 |
| Nov 4, 24 | Tarsh Simon | other | 58,500 |
| Nov 4, 24 | MCNULTY JAMES A | other | 120,968 |
| Oct 14, 24 | van Tilburg Maurice | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RENB coverage
Recent articles, reports, and earnings notes.
No research on RENB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RENB report →Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
accessnewswire.com · Sep 25
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split
accessnewswire.com · Sep 24
Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics
accessnewswire.com · Sep 11
Top 3 Health Care Stocks You'll Regret Missing In Q3
benzinga.com · Sep 9
Lunai Bioworks Inc. Retains American Defense International
accessnewswire.com · Sep 4
Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
accessnewswire.com · Aug 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.